1. Home
  2. YCBD vs LEXX Comparison

YCBD vs LEXX Comparison

Compare YCBD & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo cbdMD Inc.

YCBD

cbdMD Inc.

HOLD

Current Price

$0.39

Market Cap

6.0M

Sector

Health Care

ML Signal

HOLD

Logo Lexaria Bioscience Corp.

LEXX

Lexaria Bioscience Corp.

N/A

Current Price

$3.77

Market Cap

6.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
YCBD
LEXX
Founded
2015
2004
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.0M
6.7M
IPO Year
2018
2011

Fundamental Metrics

Financial Performance
Metric
YCBD
LEXX
Price
$0.39
$3.77
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 72.4K
54.6K
Earning Date
12-18-2026
11-27-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 39.11
N/A
EPS
N/A
★ N/A
Revenue
★ $19,190,468.00
$705,923.00
Revenue This Year
$14.24
N/A
Revenue Next Year
$30.43
$6,915.00
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 52.05
52 Week Low
$0.33
$0.35
52 Week High
$2.56
$21.60

Technical Indicators

Market Signals
Indicator
YCBD
LEXX
Relative Strength Index (RSI) 49.81 52.34
Support Level $0.33 $2.67
Resistance Level $0.53 $3.90
Average True Range (ATR) 0.03 0.42
MACD 0.01 0.24
Stochastic Oscillator 85.37 91.67

Price Performance

Historical Comparison
YCBD
LEXX

About YCBD cbdMD Inc.

cbdMD Inc is a United States based company. It owns and operates the consumer hemp-based cannabidiol (CBD) brand, cbdMD, Paw CBD as well as ATRx Labs brand of functional mushrooms. The company's product categories include CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD oils, and CBD pet products. The firm distributes its products through an e-commerce website, wholesalers, and a variety of brick-and-mortar retailers.

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

Share on Social Networks: